Clinical trials
Brain Metastases From Breast Cancer clinical trials
Below are recruiting brain metastases from breast cancer clinical trials, each written for real people, not researchers. We’re tracking 365 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05608252RecruitingPhase 1/Phase 2
Drug combination for advanced ER-positive, HER2-negative breast cancer
This Phase 1/2 study tests how well a new treatment combination (VS-6766, abemaciclib, and fulvestrant) works for metastatic or hard-to-remove breast cancer that is hormone-driven (ER/PR positive) and HER2 negative. It is mainly designed to find the safest dose and then see whether it can control the cancer after it has progressed on certain prior medicines.
Boston, MassachusettsAges 18 years+ - NCT05689619Recruiting
Silibinin after one brain metastasis surgery for lung or breast cancer
This trial studies silibinin, a natural substance, to help prevent brain metastasis from coming back after surgery. It is for people with lung (NSCLC) or breast cancer who have exactly one small brain metastasis that is fully removed and has a specific lab marker in the brain tissue.
GenovaAges 18–70 - NCT05700721RecruitingPhase 2
Niraparib and dostarlimab for cancer with growing brain spots
This trial studies whether the medicines niraparib and dostarlimab can slow advanced cancers that have active, growing brain metastases. It is meant for people whose brain tumors can be measured on MRI and who have had at least one previous treatment.
Houston, TexasAges 18 years+ - NCT05720260RecruitingPhase 2
Test immunotherapy plus hormone therapy and an AKT blocker
This trial tests whether combining immunotherapy, hormone therapy, and an AKT-blocking drug can control ER-positive advanced breast cancer in women whose cancer is resistant to hormone treatment. It may help shrink tumors and slow disease by targeting several pathways at once.
TaipeiAges 20 years+ - NCT05741164RecruitingPhase 2
Propranolol plus pembrolizumab for hard-to-treat breast cancer
This Phase 2 trial studies whether adding propranolol to pembrolizumab can “re-sensitize” tumors and slow cancer in triple-negative breast cancer that no longer responds to checkpoint immunotherapy. It may help some people whose cancer has grown despite prior pembrolizumab and chemotherapy.
Atlanta, GeorgiaAges 18 years+ - NCT05746325Recruiting
Tumor-pulse device for spinal cancer fluid spread
This trial tests whether Tumor Treating Fields (a non-surgical device that delivers treatment signals to cancer cells through the scalp/skin) can help people whose breast or lung cancer has spread into the fluid around the spine and brain. It focuses on people who have cancer cells found in spinal fluid and can safely use the device most of the day.
Jacksonville, FloridaAges 18 years+ - NCT05748834RecruitingPhase 2
Tucatinib plus Doxil for HER2-positive metastatic breast cancer
This Phase 2 study tests tucatinib (a HER2-targeted pill) plus Doxil (a chemotherapy medicine) to slow or shrink HER2-positive metastatic breast cancer that has been treated before. It may help by targeting HER2 cancer cells more effectively than past treatments alone.
Columbia, MarylandAges 18 years+ - NCT05769010RecruitingPhase 2
HER2-positive or low breast cancer brain metastasis drug study
This Phase 2 study tests SHR-A1811 in people with HER2-positive (or HER2-low) advanced breast cancer that has spread to the brain. It aims to shrink brain tumors and control the cancer in the brain, especially when there was no need for urgent local treatment like radiation or surgery.
Zhengzhou, HenanAges 18–75 - NCT05846789RecruitingPhase 2
Chemotherapy with or without tocilizumab for breast cancer
This Phase 2 trial tests whether adding tocilizumab (a drug that targets inflammation signals) to standard chemotherapy helps people with triple-negative or ER-low metastatic or locally recurring breast cancer. It’s for adults who have had up to two prior treatments for metastatic disease and who can receive standard chemo.
Atlanta, GeorgiaAges 18 years+ - NCT05866432RecruitingPhase 2
Dato-DXd for triple-negative breast cancer brain metastases
This trial studies Dato-DXd (an antibody-drug medicine) in people with triple-negative breast cancer that has spread to the brain. It aims to see how well it controls brain tumors when they are newly found or growing after other treatments.
Vienna, State of ViennaAges 18–100 - NCT05950945RecruitingPhase 3
Trastuzumab deruxtecan for HER2-low metastatic breast cancer
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
Miami Beach, FloridaAges 18 years+ - NCT05961111RecruitingEarly Phase 1
Oncolytic virus injection for advanced solid tumors
This early-phase trial tests an injection of a virus designed to attack cancer cells in people with advanced solid tumors. It is meant for situations where standard treatments have not worked (or you can’t/won’t take them) and when doctors can directly deliver the treatment to a tumor spot.
Linyi, ShandongAges 18–75 - NCT05987644RecruitingPhase 1/Phase 2
Timing of brain radiation for ALK-positive lung cancer with brain mets
This trial tests whether it is better to delay brain radiation or give it right away in people with ALK-positive lung cancer that has spread to the brain and is causing few or no symptoms. If you are starting alectinib, you may be able to join and help find the best timing for radiation.
Stanford, CaliforniaAges 18 years+ - NCT06042894RecruitingPhase 2
Study of two drugs for advanced HER2-negative breast cancer
This trial tests two experimental drugs, SI-B003 and BL-B01D1 plus SI-B003, for people with HER2-negative breast cancer that has spread or cannot be removed by surgery. It is for those who have tried standard treatments or cannot have them.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06048094RecruitingPhase 1
PET scan study for brain metastases treated with radiosurgery
This trial tests a special PET scan (18F-fluciclovine) to see how well it shows brain metastases after stereotactic radiosurgery (a precise form of radiation). It may help doctors better understand treatment effects.
Miami, FloridaAges 18 years+ - NCT06058988RecruitingPhase 2
T-DXd for people with brain cancer
This trial tests a drug called Trastuzumab Deruxtecan (T-DXd) for people with brain tumors that are either glioblastoma or have spread from other cancers. Doctors will see if T-DXd can shrink tumors or slow their growth, and they will collect tumor tissue during surgery or biopsy to study how the drug works.
New York, New YorkAges 18 years+ - NCT06072612RecruitingPhase 3
Bria-IMT plus CPI vs standard care for advanced breast cancer
This trial tests a new combination of two immunotherapy drugs (Bria-IMT and a checkpoint inhibitor) against your doctor's choice of standard treatments. It is for people with advanced breast cancer that has spread and who have already tried several prior therapies.
Phoenix, ArizonaAges 18 years+ - NCT06072807RecruitingPhase 4
Brain imaging study for ER+ breast cancer with brain tumors
This trial tests a special PET scan called FES to see if it can detect estrogen receptors in brain metastases. It may help doctors better target treatment for people with ER+ breast cancer that has spread to the brain.
New York, New YorkAges 18 years+ - NCT06075810RecruitingPhase 1
Oral MBQ-167 for advanced breast cancer
This trial tests an experimental oral drug, MBQ-167, for people with advanced breast cancer who have tried other treatments or have no standard options left. The goal is to see if the drug can help slow or stop the cancer.
Beverly Hills, CaliforniaAges 21 years+ - NCT06099769RecruitingPhase 2
Testing enzalutamide with or without mifepristone for AR-positive breast cancer
This trial tests if adding the drug mifepristone to the standard antiandrogen enzalutamide works better than enzalutamide alone or chemotherapy for people with a specific type of breast cancer that has androgen receptors. It aims to find a new targeted treatment option for triple-negative or ER-low breast cancer.
Birmingham, AlabamaAges 18 years+ - NCT06110793RecruitingPhase 1/Phase 2
Study of lenvatinib, pembrolizumab, and fulvestrant for advanced breast cancer
This trial tests a combination of three drugs (lenvatinib, pembrolizumab, and fulvestrant) for people with a certain type of advanced breast cancer that has stopped responding to previous hormone therapy. The goal is to see if this new combination can help shrink or control the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT06120283RecruitingPhase 1
Testing a new drug for breast cancer and other solid tumors
This trial tests a new oral drug (BGB-43395) alone or with other treatments for people with advanced breast cancer or other solid tumors that depend on CDK4. It aims to find safe doses and see if the drug helps shrink tumors or slow growth.
Denver, ColoradoAges 18 years+ - NCT06144346Recruiting
Radiation for limited breast cancer spread
This trial tests whether treating each spot of cancer that has spread (but only a few spots) with focused radiation can help control breast cancer. It aims to see if this approach can stop the cancer from growing further without needing strong whole-body treatments right away.
CairoAges 18–70 - NCT06201234RecruitingPhase 2
Adding elacestrant to olaparib for advanced HR+/HER2- breast cancer
This trial tests if adding a new oral medicine (elacestrant) to a standard PARP inhibitor (olaparib) works better for people with advanced or metastatic HR+/HER2- breast cancer who have a BRCA1 or BRCA2 gene mutation. The goal is to see if the combination can help control the cancer longer.
Stuttgart, Baden-WurttembergAges 18 years+
Hear when a new Brain Metastases From Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for brain metastases from breast cancer?
- Yes. Clin2 currently lists 365 recruiting brain metastases from breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a brain metastases from breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a brain metastases from breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Brain Metastases From Solid Tumors
- Liver Metastases From Colorectal Cancer
- Peritoneal Metastases From Colorectal Cancer
- Brain Metastases From Extra-cranial Solid Tumors
- Triple Negative Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.